GALECTIN THERAPEUTICS INC

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on researching and developing therapies for fibrotic conditions and cancers. The company utilizes plant-derived complex carbohydrates to create compounds that inhibit galectin proteins, particularly galectin-3. Its lead drug candidate is belapectin, which is evaluated for treating metabolic dysfunction-associated steatohepatitis with cirrhosis and portal hypertension, as well as head and neck cancers. Additionally, the company develops orally administered small-molecule inhibitors through a joint venture subsidiary. Because all drug candidates remain in clinical or preclinical development, the firm has no commercial customers and directs its therapies toward patients suffering from chronic liver disease and life-threatening malignancies.

The company is headquartered in Norcross, Georgia, near Atlanta, and maintains a laboratory facility in the Boston, Massachusetts area. Its clinical trial footprint includes more than 150 study sites established across 14 countries, with operations and patient enrollment spanning the United States, Europe, and Latin America.

Summary of the business section of Galectin Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 28, 2026, we had nine full-time employees, six of whom are involved primarily in management of our research and development and clinical trials and three who were involved primarily in management and administration of our Company.”